Journal of Clinical and Investigative Dermatology
Research Article
Breaking the Hair-Loss Barrier: Pattern-Wise Efficacy of Verilich Serum
Manne V*
Department of Skin, Hair and Laser Center, Hyderabad, Telangana, India
*Address for Correspondence:Dr. Vimala Manne, Department of Skin, Hair and Laser Center,
Hyderabad, Telangana, India. E-mail Id: manne.vimala@gmail.com
Submission:12 December, 2025
Accepted:08 January, 2026
Published:12 January, 2026
Copyright: © 2026 Manne V. This is an open access article
distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Keywords:Chronic Telogen Effluvium; Male Pattern Hair Loss; Female
Pattern Hair Loss; Androgenetic Alopecia; Verilich Serum; Topical
Treatment, Hair Loss Management; Clinical Efficacy
Abstract
Background: Chronic telogen effluvium and pattern hair loss
requires prolonged treatment duration, typically 3-6 months with
conventional therapy. This study evaluated the efficacy and safety of
Verilich serum in enhancing clinical outcomes across multiple hair loss
conditions.
Methods: A prospective observational study included 25 patients: 21 with chronic telogen effluvium (15 females, 6 males; mean age 27.8 years), 2 with male pattern hair loss, and 2 with female pattern hair loss. All patients received Verilich serum 1mL daily application combined with nutritional supplementation (iron, vitamin D3 60,000 IU weekly, methylcobalamin 500mcg daily). Pattern hair loss patients additionally received hormonal therapy or minoxidil/finasteride as indicated. Primary endpoint was time to clinical improvement defined as >50% reduction in hair shedding and negative hair pull test (<3 hairs extracted).
Results: In chronic telogen effluvium patients, 71.4% (15/21) achieved clinical improvement within 2 months, characterized by significant reduction in daily hair shedding and conversion to negative hair pull test. All pattern hair loss patients demonstrated clinical response within 3-6 months with reduced hair loss and improved density. Overall, 60% (15/25) showed accelerated response (≤2 months). Zero adverse events were reported across all groups with 100% treatment completion.
Conclusion: Verilich serum demonstrated significant efficacy in accelerating clinical improvement in chronic telogen effluvium with favorable safety profile. These findings indicate that Verilich serum may play a beneficial role within comprehensive management strategies for diverse hair loss conditions.
Methods: A prospective observational study included 25 patients: 21 with chronic telogen effluvium (15 females, 6 males; mean age 27.8 years), 2 with male pattern hair loss, and 2 with female pattern hair loss. All patients received Verilich serum 1mL daily application combined with nutritional supplementation (iron, vitamin D3 60,000 IU weekly, methylcobalamin 500mcg daily). Pattern hair loss patients additionally received hormonal therapy or minoxidil/finasteride as indicated. Primary endpoint was time to clinical improvement defined as >50% reduction in hair shedding and negative hair pull test (<3 hairs extracted).
Results: In chronic telogen effluvium patients, 71.4% (15/21) achieved clinical improvement within 2 months, characterized by significant reduction in daily hair shedding and conversion to negative hair pull test. All pattern hair loss patients demonstrated clinical response within 3-6 months with reduced hair loss and improved density. Overall, 60% (15/25) showed accelerated response (≤2 months). Zero adverse events were reported across all groups with 100% treatment completion.
Conclusion: Verilich serum demonstrated significant efficacy in accelerating clinical improvement in chronic telogen effluvium with favorable safety profile. These findings indicate that Verilich serum may play a beneficial role within comprehensive management strategies for diverse hair loss conditions.